ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Partners Aim To Make Oncology Biosimilars

by Ann M. Thayer
June 11, 2012 | APPEARED IN VOLUME 90, ISSUE 24

Dr. Reddy’s Laboratories, in India, and Merck Serono, a division of Germany’s Merck KGaA, will jointly develop generic biologic, or biosimilar, drugs. They will focus primarily on developing, manufacturing, and selling monoclonal antibodies for oncology purposes. The partners will share R&D costs and divide up worldwide commercial activities. Dr. Reddy’s will handle early product development, including Phase I clinical trials. After that, Merck Serono will assume manufacturing and development through Phase III.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment